Presentation is loading. Please wait.

Presentation is loading. Please wait.

Sirolimus and Mycophenolate Mofetil as Calcineurin Inhibitor–Free Graft-versus-Host Disease Prophylaxis for Reduced-Intensity Conditioning Umbilical Cord.

Published byΚλήμης Καλύβας Modified over 5 years ago

Similar presentations

Presentation on theme: "Sirolimus and Mycophenolate Mofetil as Calcineurin Inhibitor–Free Graft-versus-Host Disease Prophylaxis for Reduced-Intensity Conditioning Umbilical Cord."— Presentation transcript:

1 Sirolimus and Mycophenolate Mofetil as Calcineurin Inhibitor–Free Graft-versus-Host Disease Prophylaxis for Reduced-Intensity Conditioning Umbilical Cord Blood Transplantation  Nelli Bejanyan, John Rogosheske, Todd E. DeFor, Aleksandr Lazaryan, Mukta Arora, Shernan G. Holtan, Pamala A. Jacobson, Margaret L. MacMillan, Michael R. Verneris, Bruce R. Blazar, Daniel J. Weisdorf, John E. Wagner, Claudio G. Brunstein  Biology of Blood and Marrow Transplantation  Volume 22, Issue 11, Pages (November 2016) DOI: /j.bbmt Copyright © 2016 The American Society for Blood and Marrow Transplantation Terms and Conditions

2 Figure 1 Grades II to IV acute GVHD by GVHD prophylaxis.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2016 The American Society for Blood and Marrow Transplantation Terms and Conditions

3 Figure 2 Chronic GVHD by GVHD prophylaxis.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2016 The American Society for Blood and Marrow Transplantation Terms and Conditions

4 Figure 3 Infection density (number per 1000 patient days).
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2016 The American Society for Blood and Marrow Transplantation Terms and Conditions

Download ppt "Sirolimus and Mycophenolate Mofetil as Calcineurin Inhibitor–Free Graft-versus-Host Disease Prophylaxis for Reduced-Intensity Conditioning Umbilical Cord."

Similar presentations

Promising Progression-Free Survival for Patients Low and Intermediate Grade Lymphoid Malignancies after Nonmyeloablative Umbilical Cord Blood Transplantation 

Promising Progression-Free Survival for Patients Low and Intermediate Grade Lymphoid Malignancies after Nonmyeloablative Umbilical Cord Blood Transplantation 
Follistatin and Endoglin: Potential Biomarkers of Endothelial Damage and Non-Relapse Mortality after Myeloablative Allogeneic Hematopoietic Cell Transplantation.

Follistatin and Endoglin: Potential Biomarkers of Endothelial Damage and Non-Relapse Mortality after Myeloablative Allogeneic Hematopoietic Cell Transplantation.
Successful Remission Rates and Survival after Lymphodepleting Chemotherapy and Donor Lymphocyte Infusion for Relapsed Hematologic Malignancies Postallogeneic.

Successful Remission Rates and Survival after Lymphodepleting Chemotherapy and Donor Lymphocyte Infusion for Relapsed Hematologic Malignancies Postallogeneic.
Monosomal Karyotype at the Time of Diagnosis or Transplantation Predicts Outcomes of Allogeneic Hematopoietic Cell Transplantation in Myelodysplastic.

Monosomal Karyotype at the Time of Diagnosis or Transplantation Predicts Outcomes of Allogeneic Hematopoietic Cell Transplantation in Myelodysplastic.
Loss of T Follicular Helper Cells in the Peripheral Blood of Patients with Chronic Graft- versus-Host Disease  David A. Knorr, Hongbo Wang, Mukta Aurora,

Loss of T Follicular Helper Cells in the Peripheral Blood of Patients with Chronic Graft- versus-Host Disease  David A. Knorr, Hongbo Wang, Mukta Aurora,
Reduced-Intensity Conditioning Followed by Related Allografts in Hematologic Malignancies: Long-Term Outcomes Most Successful in Indolent and Aggressive.

Reduced-Intensity Conditioning Followed by Related Allografts in Hematologic Malignancies: Long-Term Outcomes Most Successful in Indolent and Aggressive.
Does the Hematopoietic Cell Transplantation Specific Comorbidity Index Predict Transplant Outcomes? A Validation Study in a Large Cohort of Umbilical.

Does the Hematopoietic Cell Transplantation Specific Comorbidity Index Predict Transplant Outcomes? A Validation Study in a Large Cohort of Umbilical.
FDG-PET Interpreted By Deauville Criteria Prior to Allogeneic Transplantation Predicts Outcomes in Patients with Relapsed or Refractory Hodgkin Lymphoma 

FDG-PET Interpreted By Deauville Criteria Prior to Allogeneic Transplantation Predicts Outcomes in Patients with Relapsed or Refractory Hodgkin Lymphoma 
Graft-Versus-Host Disease and Survival after Cord Blood Transplantation for Acute Leukemia: A Comparison of Japanese versus White Populations  Yachiyo.

Graft-Versus-Host Disease and Survival after Cord Blood Transplantation for Acute Leukemia: A Comparison of Japanese versus White Populations  Yachiyo.
Changing Trends of Unrelated Umbilical Cord Blood Transplantation for Hematologic Diseases in Patients Older than Fifty Years: A Eurocord-Center for International.

Changing Trends of Unrelated Umbilical Cord Blood Transplantation for Hematologic Diseases in Patients Older than Fifty Years: A Eurocord-Center for International.
Sympathectomy Protects Denervated Skin from Graft-Versus-Host Disease

Sympathectomy Protects Denervated Skin from Graft-Versus-Host Disease
Survival Differences between Adolescents/Young Adults and Children with B Precursor Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Cell Transplantation 

Survival Differences between Adolescents/Young Adults and Children with B Precursor Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Cell Transplantation 
Impact of Allele-Level HLA Mismatch on Outcomes in Recipients of Double Umbilical Cord Blood Transplantation  Claudio G. Brunstein, Effie W. Petersdorf,

Impact of Allele-Level HLA Mismatch on Outcomes in Recipients of Double Umbilical Cord Blood Transplantation  Claudio G. Brunstein, Effie W. Petersdorf,
Late Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation  Aazim K. Omer, Daniel J. Weisdorf, Aleksandr Lazaryan,

Late Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation  Aazim K. Omer, Daniel J. Weisdorf, Aleksandr Lazaryan,
Long-Term Results of Autologous Stem Cell Transplantation for Primary Refractory or Relapsed Hodgkin’s Lymphoma  Navneet S. Majhail, Daniel J. Weisdorf,

Long-Term Results of Autologous Stem Cell Transplantation for Primary Refractory or Relapsed Hodgkin’s Lymphoma  Navneet S. Majhail, Daniel J. Weisdorf,
Human Herpesvirus-6B Reactivation Is a Risk Factor for Grades II to IV Acute Graft- versus-Host Disease after Hematopoietic Stem Cell Transplantation:

Human Herpesvirus-6B Reactivation Is a Risk Factor for Grades II to IV Acute Graft- versus-Host Disease after Hematopoietic Stem Cell Transplantation:
Musculoskeletal, Neurologic, and Cardiopulmonary Aspects of Physical Rehabilitation in Patients with Chronic Graft-versus-Host Disease  Sean Robinson.

Musculoskeletal, Neurologic, and Cardiopulmonary Aspects of Physical Rehabilitation in Patients with Chronic Graft-versus-Host Disease  Sean Robinson.
Peripheral Blood Grafts from Unrelated Donors Are Associated with Increased Acute and Chronic Graft-versus-Host Disease without Improved Survival  Mary.

Peripheral Blood Grafts from Unrelated Donors Are Associated with Increased Acute and Chronic Graft-versus-Host Disease without Improved Survival  Mary.
Delayed immune reconstitution after allogeneic transplantation increases the risks of mortality and chronic GVHD by Nelli Bejanyan, Claudio G. Brunstein,

Delayed immune reconstitution after allogeneic transplantation increases the risks of mortality and chronic GVHD by Nelli Bejanyan, Claudio G. Brunstein,
Donor-to-Recipient ABO Mismatch Does Not Impact Outcomes of Allogeneic Hematopoietic Cell Transplantation Regardless of Graft Source  Sharat Damodar,

Donor-to-Recipient ABO Mismatch Does Not Impact Outcomes of Allogeneic Hematopoietic Cell Transplantation Regardless of Graft Source  Sharat Damodar,

Similar presentations

Ads by Google